Skip to content
Axcess News – Lifestyle
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
April 9, 2026
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
April 9, 2026
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
March 25, 2026
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
March 18, 2026
←
Previous Page
1
2